Microneedle-based integrated pharmacokinetic and pharmacodynamic evaluation platform for personalized medicine

IF 14.7 1区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

Nature Communications Pub Date : 2025-07-07 DOI:10.1038/s41467-025-61549-9

Jian Yang, Xia Gong, Ying Zheng, Hong Duan, Shuijin Chen, Tong Wu, Changqing Yi, Lelun Jiang, Hossam Haick

{"title":"Microneedle-based integrated pharmacokinetic and pharmacodynamic evaluation platform for personalized medicine","authors":"Jian Yang, Xia Gong, Ying Zheng, Hong Duan, Shuijin Chen, Tong Wu, Changqing Yi, Lelun Jiang, Hossam Haick","doi":"10.1038/s41467-025-61549-9","DOIUrl":null,"url":null,"abstract":"<p>Precision and personalized medicine for disease management necessitates real-time, continuous monitoring of biomarkers and therapeutic drugs to adjust treatment regimens based on individual patient responses. This study introduces a wearable Microneedle-based Continuous Biomarker/Drug Monitoring (MCBM) system, designed for the simultaneous, in vivo pharmacokinetic and pharmacodynamic evaluation for diabetes. Utilizing a dual-sensor microneedle and a layer-by-layer nanoenzyme immobilization strategy, the MCBM system achieves high sensitivity and specificity in measuring glucose and metformin concentrations in skin interstitial fluid (ISF). Seamless integration with a smartphone application enables real-time data analysis and feedback, fostering a pharmacologically informed approach to diabetes management. The MCBM system’s validation and in vivo trials demonstrate its precise monitoring of glucose and metformin, offering a tool for personalized treatment adjustments. Its proven biocompatibility and safety suit long-term usage. This system advances personalized diabetes care, highlighting the move towards wearables that adjust drug dosages in real-time, enhancing precision and personalized medicine.</p>","PeriodicalId":19066,"journal":{"name":"Nature Communications","volume":"81 1","pages":""},"PeriodicalIF":14.7000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Communications","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1038/s41467-025-61549-9","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Precision and personalized medicine for disease management necessitates real-time, continuous monitoring of biomarkers and therapeutic drugs to adjust treatment regimens based on individual patient responses. This study introduces a wearable Microneedle-based Continuous Biomarker/Drug Monitoring (MCBM) system, designed for the simultaneous, in vivo pharmacokinetic and pharmacodynamic evaluation for diabetes. Utilizing a dual-sensor microneedle and a layer-by-layer nanoenzyme immobilization strategy, the MCBM system achieves high sensitivity and specificity in measuring glucose and metformin concentrations in skin interstitial fluid (ISF). Seamless integration with a smartphone application enables real-time data analysis and feedback, fostering a pharmacologically informed approach to diabetes management. The MCBM system’s validation and in vivo trials demonstrate its precise monitoring of glucose and metformin, offering a tool for personalized treatment adjustments. Its proven biocompatibility and safety suit long-term usage. This system advances personalized diabetes care, highlighting the move towards wearables that adjust drug dosages in real-time, enhancing precision and personalized medicine.

Abstract Image

查看原文本刊更多论文

基于微针的个体化用药药代动力学与药效学综合评价平台

精确和个性化的疾病管理需要实时、持续地监测生物标志物和治疗药物，以根据个体患者的反应调整治疗方案。本研究介绍了一种基于可穿戴微针的生物标志物/药物连续监测（MCBM）系统，该系统旨在同时进行糖尿病的体内药代动力学和药理学评估。利用双传感器微针和逐层纳米酶固定策略，MCBM系统在测量皮肤间质液（ISF）中葡萄糖和二甲双胍浓度方面具有高灵敏度和特异性。与智能手机应用程序无缝集成，实现实时数据分析和反馈，促进糖尿病管理的药理学知情方法。MCBM系统的验证和体内试验证明了其对葡萄糖和二甲双胍的精确监测，为个性化治疗调整提供了工具。经过验证的生物相容性和安全性适合长期使用。该系统推进了个性化糖尿病护理，突出了向可穿戴设备的发展，可穿戴设备可实时调整药物剂量，提高了医疗的准确性和个性化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Communications Biological Science Disciplines-

CiteScore

24.90

自引率

2.40%

发文量

6928

审稿时长

3.7 months

期刊介绍： Nature Communications, an open-access journal, publishes high-quality research spanning all areas of the natural sciences. Papers featured in the journal showcase significant advances relevant to specialists in each respective field. With a 2-year impact factor of 16.6 (2022) and a median time of 8 days from submission to the first editorial decision, Nature Communications is committed to rapid dissemination of research findings. As a multidisciplinary journal, it welcomes contributions from biological, health, physical, chemical, Earth, social, mathematical, applied, and engineering sciences, aiming to highlight important breakthroughs within each domain.